Tyra Biosciences is a cash-burning clinical-stage biotechnology company focused on oral dabogratinib with 57% analyst upside and institutional accumulation, but a quality score of 1.2 out of 10, a put/call ratio of 88, and an implied volatility of 207% reflect extreme uncertainty around the binary clinical outcome.
Thesis pillars
- Extreme Options Market Hedging↓Deteriorating
- Oral Dabogratinib Pipeline Concentration↑Improving
- Institutional Accumulation Signal→Stable
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 3, 2026, based on the 10-K filed Mar 2, 2026
Tyra Biosciences, Inc. (TYRA) Stock Analysis
Recovery setup · Inst Constrain edge
Healthcare · Biotechnology
Sell if holding. Engine safety override at $21.52: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.5/10 and A.R:R 6.1:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 23%; Below-average business quality; Below long-term trend.
Tyra Biosciences is a clinical-stage biotech developing FGFR-targeted precision medicines, with no approved products or commercial revenue. The lead program, oral dabogratinib, is advancing through three concurrent Phase 2 trials in LG-UTUC, IR NMIBC, and achondroplasia in... Read more
Sell if holding. Engine safety override at $21.52: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.5/10 and A.R:R 6.1:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 23%; Below-average business quality; Below long-term trend. Chart setup: Death cross but MACD improving, RSI 58. Score 5.5/10, moderate confidence.
Passes 6/10 gates (positive momentum, favorable risk/reward ratio, clean insider activity, news events none recent, semi cycle peak clear, materials cycle peak clear). Fails on earnings proximity 7d<=7d. Suitability: speculative.
Recent developments
updated 2026-10-28Recent Developments — Tyra Biosciences, Inc.
Latest news
- NEWS 12 Health Care Stocks Moving In Thursday's Pre-Market Session — benzinga Oct 22, 2026 neutral
- NEWS Oppenheimer Reiterates Outperform on Tyra Biosciences, Lowers Price Target to $40 — benzinga Sep 22, 2026 positive
- NEWS HC Wainwright & Co. Maintains Buy on Tyra Biosciences, Lowers Price Target to $29 — benzinga Sep 22, 2026 neutral
- NEWS Stock Market Today: S&P 500, Dow and Nasdaq Futures Fall as Brent Hovers Near $107 and FOMC Commences Two-Day Meeting— M — benzinga Sep 15, 2026 neutral
- NEWS Stock Market Today: S&P 500, Dow and Nasdaq Futures Face Pressure as Brent Nears $108 and FOMC Commences Two-Day Meet— M — benzinga Sep 15, 2026 neutral
Generated 2026-10-28T11:53:47Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelineoral dabogratinib10-K Item 1: 'Our lead program, oral dabogratinib, was designed to be more selective for FGFR3 over FGFR1, FGFR2, and FGFR4 to minimize off-target side effects'
- HIGHSupplierthird parties10-K Item 1A: 'We rely on third parties for the manufacture of our product candidates for preclinical and clinical development.'
Material Events(8-K, last 90d)
- 2026-04-17Item 5.02LOWTyra Biosciences board increased authorized directors from nine to ten and appointed Habib J. Dable as Class II director, term expiring at 2026 annual meeting. Dable is an advisor at RA Capital Management and former CEO of Acceleron Pharma.SEC filing →
- 2026-04-02Item 5.02LOWJulia Rueb, VP Finance, designated as principal accounting officer effective April 1, 2026, succeeding CFO Alan Fuhrman in that specific role. Fuhrman continues as principal financial officer. No CFO departure.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers·1 ceiling hit
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Quality below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $21.52: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.5/10 and A.R:R 6.1:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 23%; Below-average business quality; Below long-term trend. Chart setup: Death cross but MACD improving, RSI 58. Prior stop was $20.01. Score 5.5/10, moderate confidence.
Analyst target: $41.29 (+91.8% upside). Prior stop was $20.01. Stop-loss: $20.01.
Concentration risk — Pipeline: oral dabogratinib; Concentration risk — Supplier: third parties; Quality below floor (1.6 < 4.0).
Tyra Biosciences, Inc. trades at a P/E of N/A (forward -7.8). TrendMatrix value score: 9.0/10. Verdict: Sell.
21 analysts cover TYRA with a consensus score of 4.3/5. Average price target: $47.
What does Tyra Biosciences, Inc. do?Tyra Biosciences is a clinical-stage biotech developing FGFR-targeted precision medicines, with no approved products or...
Tyra Biosciences is a clinical-stage biotech developing FGFR-targeted precision medicines, with no approved products or commercial revenue. The lead program, oral dabogratinib, is advancing through three concurrent Phase 2 trials in LG-UTUC, IR NMIBC, and achondroplasia in children. The company reported net losses of $119.9 million in 2025 and has cash expected to fund operations through at least 2027.